UK markets close in 5 hours 17 minutes

Epigenomics AG (EPGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
At close: 03:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3500
Open0.3500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3500 - 0.3500
52-week range0.3500 - 1.4400
Volume2,500
Avg. volume556
Market cap5.627M
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-0.2980
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs

    Epigenomics AG / Key word(s): Change in Forecast/ForecastEpigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs19-Sep-2022 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publication of inside information pursuant to Article 17 MAREpigenomics AG: Raise of

  • EQS Group

    Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

    EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data to be used as basis for planned PMA submission to F

  • EQS Group

    Epigenomics AG: Capital reduction planned at a ratio of 4 : 1

    Epigenomics AG / Key word(s): Corporate Action/AGM/EGM Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 09-Sep-2022 / 19:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Epigenomics AG: Capital reduction planned at a ratio of 4 : 1 Berlin, September 9, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQ